viewFutura Medical PLC

Futura Medical moves closer to commercialisation of TPR100 pain relief gel

Futura’s commercialisation partner for TPR100, Thornton & Ross, has filed the product’s marketing authorisation application with UK regulators

woman with neck pain
Clinical studies have shown the fast-acting gel to be effective

The commercialisation partner for Futura Medical PLC’s (LON:FUM) TPR100 fast-acting pain relief gel has filed the product’s marketing authorisation application with UK regulators.

If approved by the UK Medicines and Healthcare products Regulatory Agency, it would allow Huddersfield-based Thornton & Ross to make and sell the gel throughout the UK.

Thornton & Ross, a subsidiary of German group STADA, holds the exclusive rights to manufacture, distribute and market TPR100 in the UK until the product's patents expire in 2028.

READ: Futura inks pain relief deal

“The filing of this marketing authorisation application marks a very important step in the commercialisation of TPR100 in the UK,” said chief executive James Barder.

“TPR100 has the potential to be a best-in-class treatment in which the topical formulation and efficacy profile very successfully meet patient needs. We continue in commercial discussions with several potential distribution partners for territories outside of the UK.”

The plan is for TPR100, which gets to work quicker than most of its rival because of Futura's proprietary DermaSys delivery system, to be launched as an over-the-counter treatment for sprains, strains and bruises.

In clinical studies, the gel achieved “statistically significant pain relief” versus a placebo.

Quick facts: Futura Medical PLC

Price: 15.665 GBX

Market: AIM
Market Cap: £38.48 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Futura Medical PLC named herein, including the promotion by the Company of Futura Medical PLC in any Content on the Site, the Company receives...



Futura Medical kicks off work on Phase III trial for erectile dysfunction gel

James Barder, chief executive of Futura Medical PLC (LON:FUM), tells Proactive they've begun preparatory work on the first Phase III efficacy trial for MED2002 - their topical gel for erectile dysfunction (ED). The study will recruit approximately 1,000 patients with mild, moderate and...

on 27/4/18

2 min read